The dynamics of selected local inflammatory markers to talc in the treatment of malignant pleural effusions

被引:5
|
作者
Habal, Petr [1 ,2 ]
Jankovicova, Karolina [2 ,3 ]
Omran, Nedal [1 ,2 ]
Kondelkova, Katerina [2 ,3 ]
Krejsek, Jan [2 ,3 ]
Mandak, Jiri [1 ,2 ]
机构
[1] Charles Univ Prague, Fac Med Hradec Kralove, Dept Cardiac Surg, Prague, Czech Republic
[2] Univ Hosp, Hradec Kralove, Czech Republic
[3] Charles Univ Prague, Fac Med Hradec Kralove, Dept Clin Immunol & Allergy, Prague, Czech Republic
来源
BIOMEDICAL PAPERS-OLOMOUC | 2013年 / 157卷 / 04期
关键词
malignant pleural effusion; thoracoscopy; talc; sCD-163; sTLR-2; TOLL-LIKE RECEPTORS; EXPRESSION; PLEURODESIS; SURVIVAL; PATHOPHYSIOLOGY; MECHANISMS; CYTOKINES; IMMUNITY; POUDRAGE; FLUID;
D O I
10.5507/bp.2012.095
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Background. Malignant pleural effusions accumulate in the space between the visceral (inner) layer covering the lungs and the parietal (outer) layer covering the chest wall. Larger effusions compress the pulmonary parenchyma resulting in increasing dyspnoea. Treatment is always local and palliative. Among others, chemical pleurodesis using talc can be performed in selected patients. Talc is hydrated magnesium silicate (chemically H2Mg3 (SiO3)(4)) and has been used for pleurodesis since 1935. Videothoracoscopic talc powder insufflation (talc poudrage) is the most effective. However, markers of inflammatory reactions to extraneous substances like talc are not fully understood. The aim of this study was to assess the course of local inflammatory changes in the pleural cavity after talc insufflation. Methods. The Department of Cardiac Surgery of the Faculty of Medicine and University Hospital in Hradec Kralove, treated 47 patients aged 65 on average; 29 males and 18 females with proven recurrent malignant pleural effusion of various aetiologies from January 2009 to December 2010. They were retrospectively divided into group A (40 patients) without recurring effusion, and group B (7 patients) with recurring effusion and the need for thoracentesis or chest drainage during the 9-month monitoring. Results. Major findings were made in soluble forms of cell receptors. Group B showed statistically higher levels of the anti-inflammatory form of sCD-163 receptor in pleural fluid before the talc poudrage. This showed limited ability to create an adequate inflammatory response to external stimuli. This group also showed lower levels of the inflammatory form of sTLR-2 receptor immediately after the talc insufflation. This revealed low local reactivity to external stimuli. The effect of the treatment was not influenced by morphologic tumour type. No statistically significant differences in postoperative complications were found. This confirmed the safety of both videothoracoscopy and treatment. Conclusions. There was no correlation between the type of malignant affection and the outcome of the chemical pleurodesis. Patients with relapsing effusion have higher values of concentration of anti-inflammatory sCD-163 in pleural fluid even before the application of talc, and lower levels of concentration of inflammatory sTLR-2 immediately after application of talc.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 50 条
  • [21] Malignant Pleural Effusions: Mistletoe Spray Instead of Talc Poudrage?
    Shaw, Jane A.
    Koegelenberg, Coenraad F. N.
    RESPIRATION, 2018, 95 (03) : 143 - 144
  • [22] Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions
    Teixeira, Lisete Ribeiro
    Dias, Murilo B.
    Sales, Roberta K. B.
    Antonangelo, Leila
    Alvarenga, Vanessa A.
    Puka, Juliana
    Marchi, Evaldo
    Pagliarelli Acencio, Milena Marques
    LUNG, 2016, 194 (06) : 1021 - 1027
  • [23] Thoracoscopic Palliative Treatment of Malignant Pleural Effusions
    Onal, Omer
    Bilgin, Mehmet
    Hasdiraz, Leyla
    Oguzkaya, Fahri
    Kahraman, Ali
    Erdogan, Mehmet
    ERCIYES MEDICAL JOURNAL, 2009, 31 (02) : 162 - 168
  • [24] Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions
    Kolschmann, S
    Ballin, A
    Gillissen, A
    CHEST, 2005, 128 (03) : 1431 - 1435
  • [25] Predictors of talc slurry pleurodesis success in patients with malignant pleural effusions
    Santos, P. S.
    Marques, M. A.
    Cruz, C.
    Monteiro, H.
    Fradinho, F.
    REVISTA PORTUGUESA DE PNEUMOLOGIA, 2017, 23 (04) : 216 - 220
  • [26] Video-assisted talc pleurodesis for malignant pleural effusions utilizing local anesthesia and IV sedation
    Danby, CA
    Adebonojo, SA
    Moritz, DM
    CHEST, 1998, 113 (03) : 739 - 742
  • [27] Long-term effect and tolerance of talc slurry for control of malignant pleural effusions
    Prévost, A
    Costa, B
    Elamarti, R
    Nazeyrollas, P
    Mallet, F
    Yazbek, G
    Cauchois, A
    ONCOLOGY REPORTS, 2001, 8 (06) : 1327 - 1331
  • [28] Is povidone-iodine pleurodesis as effective, safe and well tolerated as talc pleurodesis for recurrent malignant pleural effusions?
    Bonser, Sophie A.
    Zhu, Michael Z. L.
    McKay, Glenn S.
    INTERDISCIPLINARY CARDIOVASCULAR AND THORACIC SURGERY, 2024, 38 (01):
  • [29] Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis
    Mager, HJ
    Maesen, B
    Verzijlbergen, F
    Schramel, F
    LUNG CANCER, 2002, 36 (01) : 77 - 81
  • [30] Treatment of malignant pleural effusions: the case for localized immunotherapy
    Donnenberg, Albert D.
    Luketich, James D.
    Dhupar, Rajeev
    Donnenberg, Vera S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7